Russia's Generium has started construction in the Vladimir region on what is being billed as Europe's largest biopharmaceutical plant.
Two key executives of Novartis AG subsidiary Alcon with responsibility for Asia were fired this week, AsianScientist reported, after confirming the action by the parent company.
Moscow is opening a gray market to allow imports of drugs intended for sale in other countries to be sold in Russia without the consent of the maker with a trademark for the product. The government hopes the move will lower pharmaceutical costs.
A report by Deutsche Welle says roughly half of the prescription drugs sold online are fake, and Russia is quickly becoming a major source of bogus medications.
China and Russia have become new targets for compulsory-licensing campaigns as an activist group widens its global challenge to Gilead's expensive Sovaldi (sofosbuvir) hepatitis C drug.
Back in the 1980s, the decade of Russia's failed occupation of Afghanistan, the Soviet military developed a novel way of treating blood clots, with trombovazima. Now, Russia's Biotechnopark in Koltsovo is producing tablets and injectables of the "Afghan drug" for the market.
Once again, more than half of the countries on the U.S. Trade Representative's Priority Watch List for insufficient intellectual-property protection are in Asia. Four other Asia countries also were named to the Watch List as being of lesser concern.
FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
South Korea's Green Cross said it has signed an agreement with Nanolek, a Russia biopharmaceutical company, to produce its biologics in a three-month-old facility said to be state-of-the-art.
Various recent reports covering the near-term and long-term outlook for the pharmaceutical industry in Asia paint a positive picture with increased revenues coming from the generics and biosimilars industries along with products as specific as human insulin from China.